Navigation Links
Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
Date:5/21/2008

Seven Abstracts Accepted for Presentation at ASCO

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold an investor and analyst briefing in conjunction with the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monday, June 2, 2008.

Participants:

-- George A. Scangos, PhD, President and Chief Executive Officer

-- Michael M. Morrissey, PhD, President of Research and Development

-- Gisela M. Schwab, MD, Executive Vice President and Chief Medical

Officer

Topics:

-- XL184 (targets: MET, VEGFR2, RET)

-- XL147 (targets: PI3K)

-- XL765 (targets: PI3K, mTOR)

-- XL647 (targets: EGFR, HER2, VEGFR2)

-- XL880* (targets: MET, VEGFR2)

-- XL281 (targets: RAF)

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are: 1-888- 286-8010 (domestic) and +1-617-801-6888 (international); the replay passcode is: 42662164.

ASCO Presentations

Saturday, May 31

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"A phase 1 study of XL647, an EGFR, HER2, VEGFR2 inhibitor,

administered orally daily to patients (pts) with advanced solid

malignancies (ASM)"

Day: Saturday, May 31

Session: Developmental Therapeutics: Molecular Therapeutics

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-1 p.m. Location: W375a

Poster Number: 5 Abstract Number: 3528

Presenter: Heather A. Wakelee, MD

-- XL880* (MET, VEGFR2) -- Poster

"A phase 2 study of the dual MET/VEGFR2 inhibitor GSK1363089 (XL880)

in patients with papillary renal carcinoma (PRC)"

Day: Saturday, May 31

Session: Genitourinary Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 5G Abstract Number: 5103

Presenter: Ramiprasad Srinivasan, MD, PhD

-- XL765 (PI3K, mTOR) -- Oral Presentation

"A phase 1 dose-escalation study of the safety, pharmacokinetics

(PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765,

administered orally to patients (pts) with advanced solid tumors"

Day: Saturday, May 31

Session: PI-3 Kinase/mTOR Directed Agents

Time: 1:45-2:15 pm

Location: W375a

Abstract Number: 3510

Presenter: Kyriakos Papadopoulis, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

Sunday, June 1

-- XL184 (RET, MET, VEGFR2) -- Oral Presentation

"A phase 1 study of XL184, a RET, VEGFR2, and MET kinase inhibitor,

in patients (pts) with advanced malignancies, including pts with

medullary thyroid cancer (MTC)"

Day: Sunday, June 1

Session: Developmental Therapeutics: Molecular Therapeutics

Time: 10-10:15 a.m.

Location: W375a

Abstract Number: 3522

Presenter: Ravi Salgia, MD, PhD

-- XL647 (EGFR, HER2, VEGFR2) -- Poster

"Activity of XL647 in clinically selected NSCLC patients (pts)

enriched for the presence of EGFR mutations: Results from phase 2"

Day: Sunday, June 1

Session: Lung Cancer -- Metastatic

Time: 2-6 p.m.

Location: S Hall A1

Poster Number: 42H Abstract Number: 8053

Presenter: Naiyer A Rizvi, MD

Monday, June 2

-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion

"Activity and tolerance of XL647 in NSCLC patients with acquired

resistance to EGFR-TKIs: Preliminary results of a phase 2 trial"

Day: Monday, June 2

Session: Lung Cancer -- Metastatic

Time (Poster): 8 a.m.-noon Location: W375e Lobby

Time (Discussion): Noon-12:15 p.m. Location: W375d

Poster Number: 9 Abstract Number: 8028

Presenter: Vincent A. Miller, MD

-- XL880* (MET, VEGFR2) -- Poster

"Preliminary activity of GSK1363089 (XL880), a dual MET/VEGFR2

inhibitor, in MET amplified poorly differentiated gastric cancer

(PDGC): Interim results of a multicenter phase 2 study"

Day: Monday, June 2

Session: Gastrointestinal (Noncolorectal) Cancer

Time: 8 a.m.-noon

Location: S Hall A1

Poster Number: 33D Abstract Number: 4572

Presenter: Minaxi P. Jhawer, MD

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):